| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 22 | 2024 | 319 | 5.390 |
Why?
|
| Kidney | 44 | 2023 | 1147 | 5.060 |
Why?
|
| Lupus Nephritis | 13 | 2023 | 77 | 3.330 |
Why?
|
| Kidney Neoplasms | 10 | 2023 | 638 | 2.390 |
Why?
|
| Kidney Glomerulus | 20 | 2023 | 122 | 2.360 |
Why?
|
| Glomerulonephritis | 16 | 2022 | 76 | 2.190 |
Why?
|
| Kidney Failure, Chronic | 9 | 2024 | 414 | 2.010 |
Why?
|
| Kidney Transplantation | 21 | 2021 | 850 | 2.000 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2023 | 437 | 1.920 |
Why?
|
| Nephrectomy | 12 | 2023 | 295 | 1.860 |
Why?
|
| Lupus Erythematosus, Systemic | 7 | 2024 | 211 | 1.840 |
Why?
|
| Thrombotic Microangiopathies | 5 | 2020 | 21 | 1.830 |
Why?
|
| Biopsy | 21 | 2021 | 1184 | 1.790 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 10 | 2023 | 35 | 1.710 |
Why?
|
| Nephritis, Interstitial | 8 | 2016 | 44 | 1.340 |
Why?
|
| Diabetic Nephropathies | 7 | 2020 | 87 | 1.290 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2020 | 219 | 1.240 |
Why?
|
| Podocytes | 11 | 2023 | 33 | 1.230 |
Why?
|
| Kidney Medulla | 2 | 2015 | 81 | 0.970 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2024 | 2 | 0.970 |
Why?
|
| Allografts | 3 | 2021 | 181 | 0.960 |
Why?
|
| Humans | 106 | 2024 | 89357 | 0.950 |
Why?
|
| Incidental Findings | 2 | 2019 | 98 | 0.930 |
Why?
|
| Hepatorenal Syndrome | 2 | 2014 | 9 | 0.900 |
Why?
|
| Lysosomes | 1 | 2024 | 111 | 0.900 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2014 | 21 | 0.900 |
Why?
|
| Graft Rejection | 9 | 2021 | 1070 | 0.890 |
Why?
|
| Bile | 2 | 2014 | 57 | 0.890 |
Why?
|
| Bilirubin | 2 | 2014 | 131 | 0.880 |
Why?
|
| Glomerulonephritis, Membranous | 6 | 2020 | 23 | 0.880 |
Why?
|
| Thrombosis | 3 | 2015 | 302 | 0.870 |
Why?
|
| Cause of Death | 2 | 2024 | 269 | 0.860 |
Why?
|
| Anemia, Sickle Cell | 2 | 2015 | 144 | 0.850 |
Why?
|
| Inflammation | 11 | 2022 | 972 | 0.830 |
Why?
|
| Complement Activation | 5 | 2020 | 81 | 0.820 |
Why?
|
| Kidney Tubules | 4 | 2014 | 92 | 0.820 |
Why?
|
| Nephrosclerosis | 2 | 2020 | 5 | 0.820 |
Why?
|
| Medical Records | 3 | 2012 | 120 | 0.810 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 4 | 2015 | 21 | 0.800 |
Why?
|
| Pathology | 2 | 2012 | 32 | 0.750 |
Why?
|
| Nephritis | 2 | 2018 | 17 | 0.740 |
Why?
|
| Autoimmunity | 3 | 2024 | 168 | 0.710 |
Why?
|
| T-Lymphocytes | 5 | 2024 | 1224 | 0.710 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 19 | 0.710 |
Why?
|
| Bowman Capsule | 2 | 2018 | 6 | 0.690 |
Why?
|
| Neurofibromatosis 2 | 1 | 2019 | 11 | 0.690 |
Why?
|
| Acute Kidney Injury | 6 | 2019 | 312 | 0.680 |
Why?
|
| Arteriosclerosis | 1 | 2020 | 112 | 0.680 |
Why?
|
| Complement Factor H | 9 | 2022 | 34 | 0.670 |
Why?
|
| Nephrotic Syndrome | 4 | 2021 | 33 | 0.670 |
Why?
|
| Cardiology | 1 | 2020 | 115 | 0.670 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2014 | 475 | 0.670 |
Why?
|
| Female | 59 | 2024 | 46202 | 0.650 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 187 | 0.640 |
Why?
|
| Male | 57 | 2024 | 42411 | 0.620 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2014 | 157 | 0.610 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 178 | 0.600 |
Why?
|
| Intraoperative Complications | 2 | 2017 | 188 | 0.600 |
Why?
|
| Adrenalectomy | 1 | 2017 | 45 | 0.600 |
Why?
|
| Capillaries | 3 | 2014 | 90 | 0.590 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 49 | 0.580 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 322 | 0.580 |
Why?
|
| Immune Complex Diseases | 5 | 2022 | 19 | 0.580 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 81 | 0.570 |
Why?
|
| Renal Dialysis | 5 | 2024 | 335 | 0.550 |
Why?
|
| Autopsy | 4 | 2024 | 122 | 0.540 |
Why?
|
| Erythrocytes | 2 | 2014 | 254 | 0.530 |
Why?
|
| Hemodynamics | 2 | 2017 | 731 | 0.530 |
Why?
|
| Precision Medicine | 1 | 2020 | 410 | 0.530 |
Why?
|
| Hemoglobin C Disease | 1 | 2015 | 5 | 0.530 |
Why?
|
| Inflammasomes | 2 | 2023 | 26 | 0.520 |
Why?
|
| Adult | 34 | 2021 | 26607 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 5 | 2017 | 275 | 0.510 |
Why?
|
| Antigen-Antibody Complex | 8 | 2021 | 87 | 0.500 |
Why?
|
| Middle Aged | 34 | 2023 | 25974 | 0.500 |
Why?
|
| Plasma Cells | 2 | 2012 | 84 | 0.490 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 98 | 0.470 |
Why?
|
| Heart Defects, Congenital | 3 | 2016 | 363 | 0.460 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 56 | 0.460 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 1840 | 0.460 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 89 | 0.450 |
Why?
|
| Autoantibodies | 5 | 2021 | 268 | 0.450 |
Why?
|
| Research Report | 2 | 2015 | 44 | 0.440 |
Why?
|
| Aged | 24 | 2023 | 19165 | 0.430 |
Why?
|
| Cysts | 1 | 2014 | 106 | 0.430 |
Why?
|
| Postoperative Care | 1 | 2014 | 231 | 0.430 |
Why?
|
| Polyomavirus | 2 | 2017 | 16 | 0.430 |
Why?
|
| Disease Progression | 11 | 2022 | 1489 | 0.420 |
Why?
|
| Algorithms | 2 | 2020 | 1877 | 0.420 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 159 | 0.420 |
Why?
|
| Mice | 32 | 2024 | 11761 | 0.390 |
Why?
|
| Macrophages | 5 | 2022 | 571 | 0.390 |
Why?
|
| Amyloidosis | 3 | 2020 | 127 | 0.390 |
Why?
|
| Laparoscopy | 4 | 2011 | 773 | 0.380 |
Why?
|
| Complement C4b | 3 | 2021 | 32 | 0.380 |
Why?
|
| Adaptive Immunity | 4 | 2019 | 167 | 0.380 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 61 | 0.380 |
Why?
|
| Immunohistochemistry | 12 | 2021 | 1799 | 0.370 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2010 | 40 | 0.370 |
Why?
|
| Carrier Proteins | 1 | 2014 | 681 | 0.360 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 162 | 0.360 |
Why?
|
| Animals | 38 | 2024 | 27371 | 0.350 |
Why?
|
| Transplantation, Homologous | 7 | 2021 | 996 | 0.340 |
Why?
|
| Retrospective Studies | 15 | 2024 | 9057 | 0.340 |
Why?
|
| Cytokines | 2 | 2021 | 803 | 0.330 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 157 | 0.330 |
Why?
|
| Glomerular Basement Membrane | 3 | 2015 | 4 | 0.330 |
Why?
|
| Stem Cells | 1 | 2012 | 372 | 0.330 |
Why?
|
| Congresses as Topic | 1 | 2010 | 113 | 0.330 |
Why?
|
| Cell Lineage | 2 | 2017 | 291 | 0.330 |
Why?
|
| Microscopy, Fluorescence | 7 | 2016 | 428 | 0.330 |
Why?
|
| Signal Transduction | 5 | 2024 | 3385 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 19 | 2024 | 3218 | 0.320 |
Why?
|
| Young Adult | 12 | 2021 | 6312 | 0.320 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1723 | 0.310 |
Why?
|
| Disease Models, Animal | 12 | 2024 | 2366 | 0.300 |
Why?
|
| Graft Survival | 4 | 2021 | 900 | 0.300 |
Why?
|
| Pathology, Surgical | 1 | 2007 | 12 | 0.300 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.300 |
Why?
|
| Polyomavirus Infections | 2 | 2017 | 28 | 0.290 |
Why?
|
| Antibodies, Antinuclear | 2 | 2006 | 83 | 0.290 |
Why?
|
| Tumor Virus Infections | 2 | 2017 | 81 | 0.290 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2006 | 10 | 0.280 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 18 | 0.280 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2006 | 15 | 0.280 |
Why?
|
| Adolescent | 12 | 2017 | 9263 | 0.280 |
Why?
|
| Fibrosis | 6 | 2022 | 234 | 0.280 |
Why?
|
| Giant Cells | 1 | 2006 | 19 | 0.270 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 160 | 0.270 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 37 | 0.270 |
Why?
|
| Creatinine | 6 | 2017 | 293 | 0.270 |
Why?
|
| Albuminuria | 6 | 2013 | 48 | 0.260 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 739 | 0.260 |
Why?
|
| Receptor, Anaphylatoxin C5a | 3 | 2015 | 21 | 0.260 |
Why?
|
| Microscopy, Electron | 5 | 2012 | 511 | 0.260 |
Why?
|
| Mice, Knockout | 12 | 2024 | 2001 | 0.260 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2013 | 60 | 0.260 |
Why?
|
| Nephritis, Hereditary | 1 | 2005 | 5 | 0.260 |
Why?
|
| Oxygen | 2 | 2013 | 743 | 0.260 |
Why?
|
| Child | 8 | 2020 | 7174 | 0.250 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2005 | 96 | 0.250 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2005 | 13 | 0.250 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2015 | 7 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 353 | 0.250 |
Why?
|
| Flow Cytometry | 2 | 2005 | 691 | 0.250 |
Why?
|
| Oximetry | 1 | 2005 | 82 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2024 | 8 | 0.240 |
Why?
|
| CD11b Antigen | 2 | 2015 | 36 | 0.240 |
Why?
|
| Leiomyosarcoma | 1 | 2005 | 45 | 0.240 |
Why?
|
| Child, Preschool | 8 | 2020 | 3731 | 0.240 |
Why?
|
| Immunity, Humoral | 3 | 2020 | 66 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2020 | 856 | 0.240 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 178 | 0.240 |
Why?
|
| Cell Movement | 5 | 2022 | 784 | 0.230 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 123 | 0.230 |
Why?
|
| Androgens | 1 | 2024 | 176 | 0.230 |
Why?
|
| Immunoglobulin G | 6 | 2021 | 465 | 0.230 |
Why?
|
| Chicago | 4 | 2018 | 1427 | 0.220 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2019 | 127 | 0.220 |
Why?
|
| Education, Medical, Graduate | 1 | 2007 | 393 | 0.220 |
Why?
|
| Sickle Cell Trait | 2 | 2015 | 21 | 0.220 |
Why?
|
| Ureteral Obstruction | 3 | 2013 | 67 | 0.220 |
Why?
|
| Pathologists | 1 | 2023 | 27 | 0.220 |
Why?
|
| Autoantigens | 3 | 2020 | 129 | 0.220 |
Why?
|
| Infant | 6 | 2020 | 3160 | 0.210 |
Why?
|
| HIV Infections | 1 | 2012 | 840 | 0.210 |
Why?
|
| Receptors, Complement 3b | 4 | 2014 | 39 | 0.210 |
Why?
|
| Peptide Fragments | 3 | 2021 | 463 | 0.210 |
Why?
|
| Immunosuppressive Agents | 4 | 2015 | 975 | 0.210 |
Why?
|
| Risk Factors | 6 | 2020 | 5499 | 0.200 |
Why?
|
| Nephrosis, Lipoid | 1 | 2021 | 6 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 200 | 0.190 |
Why?
|
| Serum Sickness | 4 | 2015 | 12 | 0.190 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2021 | 11 | 0.190 |
Why?
|
| Kidney Function Tests | 4 | 2017 | 114 | 0.190 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2017 | 22 | 0.190 |
Why?
|
| Tunica Intima | 1 | 2021 | 60 | 0.180 |
Why?
|
| Exercise Therapy | 1 | 2021 | 81 | 0.180 |
Why?
|
| Cloud Computing | 1 | 2020 | 11 | 0.180 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 130 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 890 | 0.180 |
Why?
|
| Paraproteinemias | 1 | 2020 | 15 | 0.180 |
Why?
|
| Apoptosis | 4 | 2016 | 1717 | 0.180 |
Why?
|
| Nephrons | 2 | 2010 | 17 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2010 | 20 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 323 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2015 | 430 | 0.180 |
Why?
|
| Arteries | 1 | 2021 | 180 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 23 | 0.170 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2010 | 14 | 0.170 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 14 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2020 | 347 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.160 |
Why?
|
| Diagnosis, Differential | 4 | 2006 | 1597 | 0.160 |
Why?
|
| Blood Platelets | 3 | 2010 | 150 | 0.160 |
Why?
|
| Terminology as Topic | 2 | 2017 | 221 | 0.160 |
Why?
|
| Machine Learning | 1 | 2020 | 258 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3666 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2007 | 1045 | 0.150 |
Why?
|
| WT1 Proteins | 1 | 2017 | 20 | 0.150 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 557 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 46 | 0.150 |
Why?
|
| Monocytes | 3 | 2014 | 218 | 0.150 |
Why?
|
| Glomerular Mesangium | 4 | 2018 | 18 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 329 | 0.150 |
Why?
|
| Renin | 1 | 2017 | 67 | 0.150 |
Why?
|
| BK Virus | 1 | 2017 | 23 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2017 | 100 | 0.140 |
Why?
|
| Viremia | 1 | 2017 | 49 | 0.140 |
Why?
|
| Apoferritins | 4 | 2022 | 15 | 0.140 |
Why?
|
| Biomarkers | 5 | 2017 | 1767 | 0.140 |
Why?
|
| Proteinuria | 3 | 2021 | 67 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 6811 | 0.140 |
Why?
|
| Time Factors | 9 | 2018 | 5338 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 198 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2018 | 8241 | 0.140 |
Why?
|
| Health Information Systems | 1 | 2016 | 2 | 0.140 |
Why?
|
| DNA, Viral | 1 | 2017 | 262 | 0.140 |
Why?
|
| Lymphocyte Depletion | 2 | 2013 | 98 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 153 | 0.130 |
Why?
|
| Data Mining | 1 | 2016 | 43 | 0.130 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 15 | 0.130 |
Why?
|
| Cytogenetics | 2 | 2005 | 27 | 0.130 |
Why?
|
| Carboxypeptidases | 1 | 2015 | 35 | 0.130 |
Why?
|
| Prognosis | 7 | 2021 | 3783 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 196 | 0.130 |
Why?
|
| Microvessels | 1 | 2015 | 69 | 0.130 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 56 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2019 | 689 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2021 | 717 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2019 | 449 | 0.130 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 233 | 0.130 |
Why?
|
| Germinal Center | 2 | 2016 | 55 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 136 | 0.120 |
Why?
|
| Vimentin | 1 | 2014 | 46 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2021 | 201 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2015 | 53 | 0.120 |
Why?
|
| Chemotaxis | 1 | 2014 | 73 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2016 | 471 | 0.120 |
Why?
|
| Hemolysis | 1 | 2014 | 64 | 0.120 |
Why?
|
| Complement C3b | 1 | 2014 | 5 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2014 | 11 | 0.120 |
Why?
|
| Liver Failure | 1 | 2014 | 67 | 0.120 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 71 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2014 | 192 | 0.110 |
Why?
|
| Pulmonary Artery | 2 | 2006 | 319 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 204 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2015 | 170 | 0.110 |
Why?
|
| Curcumin | 1 | 2013 | 17 | 0.110 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 244 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 851 | 0.110 |
Why?
|
| Losartan | 2 | 2010 | 30 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 969 | 0.110 |
Why?
|
| Jaundice | 1 | 2013 | 14 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 135 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 75 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 71 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 181 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 167 | 0.110 |
Why?
|
| Collagen Type IV | 2 | 2019 | 26 | 0.110 |
Why?
|
| Renin-Angiotensin System | 2 | 2010 | 81 | 0.110 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 35 | 0.100 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 231 | 0.100 |
Why?
|
| Syndecan-1 | 1 | 2012 | 16 | 0.100 |
Why?
|
| CD3 Complex | 1 | 2012 | 134 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2020 | 2486 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2019 | 299 | 0.100 |
Why?
|
| Receptors, Complement | 2 | 2014 | 46 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2012 | 102 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 191 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2016 | 398 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 131 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2012 | 172 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 345 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2014 | 2284 | 0.100 |
Why?
|
| Immunophenotyping | 3 | 2013 | 217 | 0.100 |
Why?
|
| Critical Care | 1 | 2014 | 382 | 0.090 |
Why?
|
| Aging | 3 | 2023 | 718 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 242 | 0.090 |
Why?
|
| United States | 5 | 2022 | 6989 | 0.090 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 143 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 1574 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 424 | 0.090 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cicatrix | 1 | 2011 | 68 | 0.090 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 14 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 445 | 0.090 |
Why?
|
| Renal Artery | 1 | 2011 | 52 | 0.090 |
Why?
|
| Clone Cells | 1 | 2010 | 214 | 0.090 |
Why?
|
| Ventilator Weaning | 1 | 2010 | 24 | 0.090 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 41 | 0.090 |
Why?
|
| Rifampin | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cardiac Output | 2 | 2010 | 156 | 0.090 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2010 | 12 | 0.090 |
Why?
|
| Tetralogy of Fallot | 1 | 2010 | 44 | 0.090 |
Why?
|
| Ice | 1 | 2010 | 11 | 0.090 |
Why?
|
| Immunoglobulin A | 1 | 2010 | 83 | 0.090 |
Why?
|
| Complement C3 | 2 | 2007 | 58 | 0.090 |
Why?
|
| Antigens, CD | 3 | 2014 | 466 | 0.090 |
Why?
|
| Angiomyolipoma | 1 | 2010 | 17 | 0.090 |
Why?
|
| Peer Review | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ergocalciferols | 1 | 2010 | 38 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 598 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 118 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 699 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2010 | 120 | 0.080 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2010 | 36 | 0.080 |
Why?
|
| Canada | 1 | 2010 | 208 | 0.080 |
Why?
|
| Receptors, Fc | 1 | 2009 | 32 | 0.080 |
Why?
|
| Vitamins | 1 | 2010 | 83 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 321 | 0.080 |
Why?
|
| Palatine Tonsil | 2 | 2021 | 30 | 0.080 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 82 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2015 | 445 | 0.080 |
Why?
|
| CD55 Antigens | 1 | 2009 | 21 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2010 | 575 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 127 | 0.080 |
Why?
|
| Prednisone | 2 | 2010 | 259 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 275 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 688 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 141 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2022 | 460 | 0.080 |
Why?
|
| Ureter | 1 | 2009 | 93 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1719 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2008 | 32 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 382 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1976 | 0.080 |
Why?
|
| Hypertension | 1 | 2014 | 745 | 0.080 |
Why?
|
| Neoplasms | 1 | 2003 | 3041 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 53 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 784 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 374 | 0.070 |
Why?
|
| Pulse | 1 | 2006 | 17 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2062 | 0.070 |
Why?
|
| Base Sequence | 1 | 2010 | 2327 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 280 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2019 | 2303 | 0.070 |
Why?
|
| Neprilysin | 1 | 2006 | 41 | 0.070 |
Why?
|
| Mucin-1 | 1 | 2006 | 45 | 0.070 |
Why?
|
| Rheumatic Heart Disease | 1 | 2006 | 30 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2017 | 342 | 0.070 |
Why?
|
| Brain | 2 | 2021 | 2285 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3027 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2007 | 117 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2006 | 83 | 0.070 |
Why?
|
| Benzophenoneidum | 1 | 2005 | 1 | 0.070 |
Why?
|
| Organelles | 1 | 2006 | 56 | 0.070 |
Why?
|
| Mycobacterium avium Complex | 1 | 2005 | 6 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 2018 | 0.070 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2005 | 3 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2024 | 751 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2005 | 65 | 0.060 |
Why?
|
| Lisinopril | 1 | 2005 | 4 | 0.060 |
Why?
|
| Chemokines | 2 | 2021 | 74 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2005 | 24 | 0.060 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2005 | 12 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2005 | 122 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2005 | 59 | 0.060 |
Why?
|
| Karyotyping | 1 | 2005 | 253 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 262 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2005 | 55 | 0.060 |
Why?
|
| Hematuria | 1 | 2005 | 50 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 277 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 91 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2005 | 48 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 306 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 645 | 0.060 |
Why?
|
| Phenotype | 3 | 2017 | 2440 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 922 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 313 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 110 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2005 | 111 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 98 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2006 | 244 | 0.060 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 195 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 159 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 237 | 0.060 |
Why?
|
| Image Cytometry | 1 | 2023 | 12 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2010 | 2884 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2005 | 354 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2758 | 0.060 |
Why?
|
| 12E7 Antigen | 1 | 2003 | 1 | 0.060 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2003 | 4 | 0.060 |
Why?
|
| Myogenin | 1 | 2003 | 5 | 0.060 |
Why?
|
| Thy-1 Antigens | 1 | 2003 | 16 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 2015 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2019 | 950 | 0.060 |
Why?
|
| Keratins | 1 | 2003 | 63 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 48 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2003 | 42 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2005 | 195 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 4289 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2023 | 301 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 447 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 167 | 0.050 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 358 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 329 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 85 | 0.050 |
Why?
|
| Complement Pathway, Alternative | 1 | 2021 | 13 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 34 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 230 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2021 | 36 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 1176 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3448 | 0.050 |
Why?
|
| Physical Conditioning, Animal | 1 | 2021 | 19 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 377 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 332 | 0.050 |
Why?
|
| Reperfusion | 1 | 2021 | 32 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2340 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 74 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 780 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 165 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2021 | 168 | 0.050 |
Why?
|
| Paraproteins | 1 | 2020 | 6 | 0.050 |
Why?
|
| Antibodies | 2 | 2015 | 353 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1047 | 0.040 |
Why?
|
| Solutions | 1 | 2020 | 86 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2015 | 2872 | 0.040 |
Why?
|
| Agrin | 1 | 2019 | 6 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 44 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2019 | 38 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2019 | 73 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 148 | 0.040 |
Why?
|
| Carcinoma | 1 | 2003 | 443 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 89 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 1901 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 72 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2624 | 0.040 |
Why?
|
| Laminin | 1 | 2019 | 89 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 2010 | 268 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2018 | 25 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 179 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1862 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 127 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 50 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2017 | 49 | 0.040 |
Why?
|
| Plasma | 1 | 2017 | 51 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2017 | 47 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 169 | 0.040 |
Why?
|
| Protein Domains | 1 | 2017 | 134 | 0.040 |
Why?
|
| Viral Load | 1 | 2017 | 145 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2010 | 727 | 0.040 |
Why?
|
| Mice, Inbred NZB | 1 | 2016 | 13 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2017 | 36 | 0.040 |
Why?
|
| Laser Capture Microdissection | 1 | 2016 | 20 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 1088 | 0.040 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2016 | 37 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 630 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1714 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1549 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 63 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 599 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 433 | 0.030 |
Why?
|
| Data Curation | 1 | 2016 | 3 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2010 | 466 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 352 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 17 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 24 | 0.030 |
Why?
|
| Biological Phenomena | 1 | 2016 | 3 | 0.030 |
Why?
|
| Virus Replication | 1 | 2017 | 324 | 0.030 |
Why?
|
| Nephrologists | 1 | 2016 | 10 | 0.030 |
Why?
|
| Incidence | 2 | 2014 | 1595 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 89 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2010 | 900 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2011 | 396 | 0.030 |
Why?
|
| Heart Function Tests | 2 | 2006 | 33 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2016 | 49 | 0.030 |
Why?
|
| Complement C5a | 1 | 2015 | 24 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 435 | 0.030 |
Why?
|
| Heart Failure | 1 | 2005 | 1185 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 983 | 0.030 |
Why?
|
| CD18 Antigens | 1 | 2015 | 22 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 32 | 0.030 |
Why?
|
| Melanoma | 1 | 2019 | 468 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 28 | 0.030 |
Why?
|
| Brachiocephalic Veins | 1 | 2015 | 34 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 49 | 0.030 |
Why?
|
| Fistula | 1 | 2015 | 42 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 136 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 138 | 0.030 |
Why?
|
| Data Collection | 1 | 2016 | 375 | 0.030 |
Why?
|
| Rituximab | 1 | 2015 | 119 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 209 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 318 | 0.030 |
Why?
|
| United Kingdom | 1 | 2014 | 164 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 44 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 302 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1412 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 193 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1488 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 129 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 43 | 0.030 |
Why?
|
| Atrophy | 1 | 2013 | 120 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 266 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 289 | 0.030 |
Why?
|
| Models, Biological | 2 | 2011 | 1765 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 684 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 448 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 199 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 841 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2012 | 149 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 988 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 87 | 0.030 |
Why?
|
| Global Health | 1 | 2014 | 187 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 293 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1194 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1431 | 0.020 |
Why?
|
| Palliative Care | 1 | 2014 | 264 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 784 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1652 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2014 | 494 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 610 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 871 | 0.020 |
Why?
|
| Oliguria | 1 | 2010 | 6 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 543 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1150 | 0.020 |
Why?
|
| Angiotensin I | 1 | 2010 | 7 | 0.020 |
Why?
|
| Suspensions | 1 | 2010 | 6 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 387 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 15 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1242 | 0.020 |
Why?
|
| Mesangial Cells | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2010 | 18 | 0.020 |
Why?
|
| California | 1 | 2010 | 144 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2010 | 24 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 54 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2010 | 51 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2010 | 32 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2010 | 70 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 47 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2010 | 50 | 0.020 |
Why?
|
| Warm Ischemia | 1 | 2010 | 31 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1120 | 0.020 |
Why?
|
| Syndactyly | 1 | 2009 | 12 | 0.020 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 34 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 567 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1072 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 72 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 124 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 125 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 102 | 0.020 |
Why?
|
| World Health Organization | 1 | 2010 | 106 | 0.020 |
Why?
|
| Microvilli | 1 | 2009 | 43 | 0.020 |
Why?
|
| Fibronectins | 1 | 2010 | 101 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2009 | 34 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 157 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 183 | 0.020 |
Why?
|
| CD59 Antigens | 1 | 2009 | 17 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 306 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 956 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 251 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 266 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2009 | 274 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 230 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 253 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2009 | 171 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 683 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 261 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 479 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 582 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2415 | 0.020 |
Why?
|
| Arterioles | 1 | 2008 | 22 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2008 | 14 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 170 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 576 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 502 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 44 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 244 | 0.020 |
Why?
|
| Heart Rate | 1 | 2010 | 495 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 324 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2566 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 815 | 0.020 |
Why?
|
| Thermodilution | 1 | 2006 | 21 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 949 | 0.020 |
Why?
|
| Nuclear Pore | 1 | 2006 | 11 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2362 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 1135 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 836 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1224 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2661 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 199 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 3018 | 0.020 |
Why?
|
| Epithelium | 1 | 2006 | 325 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 1144 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 106 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 788 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2007 | 298 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 306 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2017 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 186 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 414 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 494 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1870 | 0.010 |
Why?
|